Drugs / HRS-4729
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06762600 | Jan 2025 → Mar 2026 | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07690826 | Jul 2026 → Mar 2027 expected | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07660848 | Jul 2026 → Mar 2028 expected | metabolic dysfunction-associated steatohepatitis | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-4729 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06762600 ↗ |
| Route | Subcutaneous | “Single and Multiple Subcutaneous Injections of HRS-4729 Injection” NCT06762600 ↗ |